Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSIST: SABER-Bupivacaine for Postoperative Pain
NCT02574520Phase 3Completed
- Sponsor
- DURECT Corporation
- Start
- Nov 2015
- Primary completion
- Jun 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bimatoprost in postoperative pain (4 arms), sponsored by DURECT Corporation. Primary endpoint: Pain Intensity on Movement From 0-48 Hours Post-Treatment. Started Nov 2015; status: completed.
02
Drugs
bimatoprost
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02574520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574520.